CD4 and neoplasm: In our animal experiments of antitumor immunotherapy that targeting CD4+CD25+ TR cells, to our surprise, we did not find an increase of CD4+CD25+/CD4+ in peripheral blood of tumor bearing BALB/c or C57BL/6 mice, this is not in accordance with the increase of the proportion in cancer patients as reported by Wolf et al [11].